maraviroc 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals CCR5 (Chemokine CC motif receptor 5) receptor antagonists 1635 376348-65-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • MD6P741W8A
  • UK-427857
  • maravirok
  • marawirok
  • maraviroc
  • celsentri
  • selzentry
Maraviroc is a member of a therapeutic class called CCR5 co-receptor antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the cell membrane, preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. CXCR4-tropic and dual-tropic HIV-1 entry is not inhibited by maraviroc.
  • Molecular weight: 513.68
  • Formula: C29H41F2N5O
  • CLOGP: 3.26
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 1
  • TPSA: 63.05
  • ALOGS: -4.68
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 33.37 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 23 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.80 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.957 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 42.756 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.567 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.992 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 56.070 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 66.410 % High 1
herg hERG pIC50 4.629 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.016 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 16.331 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 63.850 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,GRK2,PDK1,PDK2,PDK4,PRKDC 11
kinase-selectivity-class PDK1 1
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 8.279 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 14.421 High 1
mh-clint Mouse hepatocyte intrinsic clearance 7.047 High 1
mppb Mouse plasma protein binding (% unbound) 55.500 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 21.086 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 58.210 % High 1
rat-kpuu-brain Rat brain Kpuu 0.010 % High 1
rh-clint Rat hepatocyte intrinsic clearance 2.924 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.430 % High 1
rppb Rat plasma protein binding (% unbound) 62.020 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 893.305 uM High 1

Approvals:

DateAgencyCompanyOrphan
Aug. 6, 2007 FDA VIIV HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Viral mutation identified 130.83 54.77 22 937 2003 90625485
Virologic failure 128.77 54.77 22 937 2202 90625286
Pathogen resistance 117.26 54.77 25 934 8090 90619398
Abortion spontaneous 106.05 54.77 34 925 54022 90573466
Exposure during pregnancy 73.81 54.77 40 919 238370 90389118
Lipodystrophy acquired 67.52 54.77 12 947 1502 90625986
Treatment noncompliance 60.05 54.77 22 937 51705 90575783
Antiviral drug level below therapeutic 57.52 54.77 7 952 59 90627429

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Virologic failure 294.96 25.40 63 2267 3931 42615074
Viral mutation identified 242.79 25.40 52 2278 3279 42615726
Pathogen resistance 127.26 25.40 40 2290 11410 42607595
Drug resistance 90.86 25.40 42 2288 34206 42584799
Immune reconstitution inflammatory syndrome 78.62 25.40 27 2303 10116 42608889
Blood HIV RNA increased 72.83 25.40 17 2313 1574 42617431
Progressive multifocal leukoencephalopathy 53.34 25.40 21 2309 11515 42607490
CSF HIV escape syndrome 44.47 25.40 8 2322 200 42618805
Viral load increased 44.06 25.40 13 2317 2984 42616021
Treatment noncompliance 37.10 25.40 24 2306 37648 42581357
HIV-associated neurocognitive disorder 34.39 25.40 7 2323 341 42618664
Hodgkin's disease 33.46 25.40 8 2322 820 42618185
Anal cancer 32.36 25.40 7 2323 458 42618547
Lymphoedema 30.06 25.40 11 2319 4937 42614068
Immunodeficiency 29.29 25.40 12 2318 7278 42611727
Superinfection bacterial 29.26 25.40 8 2322 1396 42617609
Multiple-drug resistance 29.24 25.40 12 2318 7310 42611695
Viral load abnormal 28.41 25.40 5 2325 110 42618895
Congenital renal disorder 28.36 25.40 5 2325 111 42618894
Treatment failure 28.23 25.40 25 2305 62599 42556406
Retinitis pigmentosa 28.10 25.40 4 2326 20 42618985
Kidney enlargement 27.74 25.40 7 2323 896 42618109
Hepatic failure 27.39 25.40 20 2310 38080 42580925
Acquired immunodeficiency syndrome 26.29 25.40 6 2324 502 42618503
Syphilis 25.48 25.40 6 2324 576 42618429

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Virologic failure 345.28 30.06 65 2606 4887 110581741
Viral mutation identified 327.05 30.06 61 2610 4358 110582270
Pathogen resistance 198.67 30.06 52 2619 17620 110569008
Drug resistance 117.66 30.06 46 2625 56328 110530300
Immune reconstitution inflammatory syndrome 96.36 30.06 29 2642 16197 110570431
CSF HIV escape syndrome 74.90 30.06 12 2659 345 110586283
Treatment noncompliance 74.58 30.06 36 2635 72954 110513674
Viral load increased 68.53 30.06 16 2655 3374 110583254
Abortion spontaneous 68.04 30.06 27 2644 34255 110552373
Progressive multifocal leukoencephalopathy 65.13 30.06 24 2647 24932 110561696
Blood HIV RNA increased 64.20 30.06 14 2657 2174 110584454
Drug interaction 53.62 30.06 63 2608 500120 110086508
Antiviral drug level below therapeutic 52.27 30.06 7 2664 54 110586574
HIV-associated neurocognitive disorder 45.62 30.06 8 2663 400 110586228
CD4 lymphocytes decreased 44.44 30.06 11 2660 2963 110583665
CSF test abnormal 40.52 30.06 8 2663 764 110585864
Hyperbilirubinaemia 40.22 30.06 18 2653 30653 110555975
Generalised anxiety disorder 40.12 30.06 10 2661 2769 110583859
Hodgkin's disease 40.04 30.06 8 2663 812 110585816
Lipodystrophy acquired 39.86 30.06 11 2660 4513 110582115
Multiple-drug resistance 39.27 30.06 14 2657 13221 110573407
Superinfection bacterial 36.48 30.06 9 2662 2392 110584236
Social avoidant behaviour 33.60 30.06 10 2661 5359 110581269
Acquired immunodeficiency syndrome 33.27 30.06 6 2665 352 110586276
Viral load abnormal 32.80 30.06 5 2666 103 110586525
Lymphoedema 30.45 30.06 12 2659 14917 110571711
White matter lesion 30.40 30.06 8 2663 2746 110583882
Pancytopenia 30.36 30.06 31 2640 209582 110377046

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AX09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Other antivirals
FDA MoA N0000175445 Chemokine Co-receptor 5 Antagonists
FDA EPC N0000175572 CCR5 Co-receptor Antagonist
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D019380 Anti-HIV Agents
MeSH PA D023581 HIV Fusion Inhibitors
MeSH PA D065100 CCR5 Receptor Antagonists
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:59886 HIV fusion inhibitor
CHEBI has role CHEBI:63673 chemokine receptor 5 antagonist

Related Drugs by ATC class:

J05AX Other antivirals 15 drugs
amenamevirbaloxavir marboxilbulevirtideenfuvirtidefavipiravirfostemsaviribalizumabinosine pranobexlenacapavirletermovirmaribavirmoroxydine show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
CCR5 Tropic Drug Resistant HIV Infection indication
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Infectious disease contraindication 40733004
Viral hepatitis C contraindication 50711007 DOID:1883
Acute nephropathy contraindication 58574008
Chronic type B viral hepatitis contraindication 61977001
Chronic renal failure syndrome contraindication 90688005
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.8 Basic
pKa2 5.07 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
C-C chemokine receptor type 5 GPCR ANTAGONIST Kd 7.60 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.11 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 4.76 CHEMBL
C-C chemokine receptor type 5 GPCR IC50 8.28 CHEMBL
C-C chemokine receptor type 5 GPCR Ki 9.62 CHEMBL

External reference:

IDSource
4026629 VUID
N0000179791 NUI
D06670 KEGG_DRUG
4026629 VANDF
C1667052 UMLSCUI
CHEBI:63608 CHEBI
CHEMBL256907 ChEMBL_ID
D000077592 MESH_DESCRIPTOR_UI
DB04835 DRUGBANK_ID
806 IUPHAR_LIGAND_ID
8450 INN_ID
MD6P741W8A UNII
3002977 PUBCHEM_CID
620216 RXNORM
118030 MMSL
24072 MMSL
356432 MMSL
d06852 MMSL
012282 NDDF
427805000 SNOMEDCT_US
429603001 SNOMEDCT_US
MD6P741W8A INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 31722-579 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 31722-580 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
SELZENTRY HUMAN PRESCRIPTION DRUG LABEL 1 49702-223 TABLET, FILM COATED 150 mg ORAL NDA 30 sections
SELZENTRY HUMAN PRESCRIPTION DRUG LABEL 1 49702-224 TABLET, FILM COATED 300 mg ORAL NDA 30 sections
SELZENTRY HUMAN PRESCRIPTION DRUG LABEL 1 50090-6238 TABLET, FILM COATED 150 mg ORAL NDA 30 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 50090-8005 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 50090-8010 TABLET, FILM COATED 150 mg ORAL ANDA 30 sections
SELZENTRY HUMAN PRESCRIPTION DRUG LABEL 1 54868-5809 TABLET, FILM COATED 300 mg ORAL NDA 32 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 68475-007 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 68475-008 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 68554-3079 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 68554-3080 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 70710-1930 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 70710-1931 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 72319-024 TABLET, FILM COATED 150 mg ORAL ANDA 30 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 72319-025 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 72865-231 TABLET, FILM COATED 150 mg ORAL ANDA 31 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 72865-232 TABLET, FILM COATED 300 mg ORAL ANDA 31 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 73141-024 TABLET, FILM COATED 150 mg ORAL ANDA 30 sections
Maraviroc HUMAN PRESCRIPTION DRUG LABEL 1 73141-025 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections